Figure S11 from Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy

2026 Open access

Read full text
Authors: Gracia Gracia, Enyuan Cao, Daniel Yuen, Vilena D.M. Ferreira, Moore Z. Chen, Danielle Senyschyn, Justine D. Mintern, Angus P. R. Johnston, David W. Kang, Orlagh M. Feeney, Christopher J.H. Porter
DOI: 10.1158/2326-6066.31484171
Cited by: 0

Abstract

αTIM3 monotherapy has limited efficacy in CT26/HAS tumour mice regardless of dose route.

Fields of Study & Subjects

Proteoglycans and glycosaminoglycans research Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses

Publication details

Publication date
4 March 2026
Language
EN